Switch theme
Sign up to access all valuation multiples
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
2015
41
LTM Revenue $5.6M
Last FY EBITDA -$24.1M
-$18.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Surrozen has a last 12-month revenue (LTM) of $5.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Surrozen achieved revenue of $10.7M and an EBITDA of -$24.1M.
Surrozen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Surrozen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.6M | XXX | $10.7M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$24.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -226% | XXX | XXX | XXX |
| EBIT | -$34.6M | XXX | -$25.5M | XXX | XXX | XXX |
| EBIT Margin | -621% | XXX | -240% | XXX | XXX | XXX |
| Net Profit | -$56.8M | XXX | -$63.6M | XXX | XXX | XXX |
| Net Margin | -1022% | XXX | -597% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Surrozen's stock price is $9.
Surrozen has current market cap of $75.4M, and EV of -$18.2M.
See Surrozen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$18.2M | $75.4M | XXX | XXX | XXX | XXX | $-13.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Surrozen has market cap of $75.4M and EV of -$18.2M.
Surrozen's trades at -1.7x EV/Revenue multiple, and 0.8x EV/EBITDA.
Equity research analysts estimate Surrozen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Surrozen has a P/E ratio of -1.3x.
See valuation multiples for Surrozen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $75.4M | XXX | $75.4M | XXX | XXX | XXX |
| EV (current) | -$18.2M | XXX | -$18.2M | XXX | XXX | XXX |
| EV/Revenue | -3.3x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSurrozen's last 12 month revenue growth is -96%
Surrozen's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.9M for the same period.
Surrozen's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Surrozen's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Surrozen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -96% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -226% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -322% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 198% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 340% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surrozen acquired XXX companies to date.
Last acquisition by Surrozen was XXXXXXXX, XXXXX XXXXX XXXXXX . Surrozen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Surrozen founded? | Surrozen was founded in 2015. |
| Where is Surrozen headquartered? | Surrozen is headquartered in United States of America. |
| How many employees does Surrozen have? | As of today, Surrozen has 41 employees. |
| Who is the CEO of Surrozen? | Surrozen's CEO is Mr. Craig C. Parker. |
| Is Surrozen publicy listed? | Yes, Surrozen is a public company listed on NAS. |
| What is the stock symbol of Surrozen? | Surrozen trades under SRZN ticker. |
| When did Surrozen go public? | Surrozen went public in 2021. |
| Who are competitors of Surrozen? | Similar companies to Surrozen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Surrozen? | Surrozen's current market cap is $75.4M |
| What is the current revenue of Surrozen? | Surrozen's last 12 months revenue is $5.6M. |
| What is the current revenue growth of Surrozen? | Surrozen revenue growth (NTM/LTM) is -96%. |
| What is the current EV/Revenue multiple of Surrozen? | Current revenue multiple of Surrozen is -3.3x. |
| Is Surrozen profitable? | Yes, Surrozen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
